- Home
- BQ vs ATXI Comparison
BQ vs ATXI Comparison
Compare BQ & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- ATXI
- Stock Information
- Founded
- BQ 2008
- ATXI 2015
- Country
- BQ China
- ATXI United States
- Employees
- BQ N/A
- ATXI N/A
- Industry
- BQ Other Specialty Stores
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- ATXI Health Care
- Exchange
- BQ Nasdaq
- ATXI Nasdaq
- Market Cap
- BQ 3.7M
- ATXI 3.7M
- IPO Year
- BQ 2020
- ATXI 2017
- Fundamental
- Price
- BQ $3.08
- ATXI $1.36
- Analyst Decision
- BQ
- ATXI
- Analyst Count
- BQ 0
- ATXI 0
- Target Price
- BQ N/A
- ATXI N/A
- AVG Volume (30 Days)
- BQ 61.7K
- ATXI 1.1M
- Earning Date
- BQ 03-04-2025
- ATXI 03-17-2025
- Dividend Yield
- BQ N/A
- ATXI N/A
- EPS Growth
- BQ N/A
- ATXI N/A
- EPS
- BQ N/A
- ATXI N/A
- Revenue
- BQ $81,208,354.00
- ATXI N/A
- Revenue This Year
- BQ N/A
- ATXI N/A
- Revenue Next Year
- BQ N/A
- ATXI N/A
- P/E Ratio
- BQ N/A
- ATXI N/A
- Revenue Growth
- BQ N/A
- ATXI N/A
- 52 Week Low
- BQ $2.32
- ATXI $1.22
- 52 Week High
- BQ $7.40
- ATXI $15.00
- Technical
- Relative Strength Index (RSI)
- BQ 44.47
- ATXI 41.78
- Support Level
- BQ $2.95
- ATXI $1.33
- Resistance Level
- BQ $3.39
- ATXI $1.44
- Average True Range (ATR)
- BQ 0.31
- ATXI 0.09
- MACD
- BQ -0.02
- ATXI 0.02
- Stochastic Oscillator
- BQ 17.19
- ATXI 63.64
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.